Please assess the completion status of the following clinical trial:

Trial Title: Hespecta Vaccination in HPV+ Tumors or Malignant Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically documented evidence of HPV16 positive (pre)malignant lesion following standard treatment~2. Patient with a tumor should have no evidence of residual disease based on physical examination at the completion of curative intent therapy~3. At least four weeks and less than twelve weeks after last anti-tumor treatment~4. Willing and able to comply with the protocol and to provide informed consent in accordance with institutional and regulatory guidelines~5. Patients must be 18 years or older.~6. Patients of child-bearing potential should test negative using a serum pregnancy test and agree to utilize effective contraception during the entire treatment and follow-up period of the study (up to 2 months after the last vaccination)~7. Patients must be in good general health and ambulatory, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~1. Radiotherapy, chemotherapy or other potentially immunosuppressive therapy administered within 4 weeks prior to the enrolment visit~2. History of an autoimmune disease or other systemic intercurrent disease that might affect the immunocompetence of the patient, or patients receiving immunosuppressive therapy, except for topical application~3. History of a second malignancy except curatively treated low-stage tumors with a histology that can be differentiated from the current tumor or premalignant lesion~4. Receipt of another investigational product within the previous 4 weeks or at any time during the study period.~5. Receipt of prior HPV directed immunotherapy~6. Hematology and biochemistry:~   * Absolute Neutrophil Count (ANC) \< 1.5 x 109/L, or platelet count \< 100 x 109/L or hemoglobin \< 6 mmol/L.~  * Serum (total) bilirubin \> 2 x upper normal limit (ULN);~  * Aspartate Aminotransferase (ASAT) or Alanine Aminotransferase (ALAT) \> 2.5 x ULN;~  * Alkaline phosphatase levels \> 2.5 x ULN;~  * Serum creatinine \> ULN or calculated clearance \</= 40 mL/min/1.73 m2 for patients with serum creatinine levels above the institutional normal value~7. Human immunodeficiency virus (HIV), chronic hepatitis B or C infection.~8. Any condition that in the opinion of the investigator could interfere with the conduct of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hespecta (Type: EXPERIMENTAL): Four dose groups of Hespecta

Based on this trial design, predict the completion outcome and termination type (if applicable).